Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and ASTX727 in Treatment-Naïve High-Risk MDS or CMML
NCT04655755Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2021
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2021; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT04655755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04655755.